Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 20/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16014451 | 0.90 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL16014356 | 0.85 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL21327825 | 0.84 | CYP11B1 (0.73) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL14789870 | 0.81 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL31260128 | 0.81 | CYP11B1 (0.68) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL16014417 | 0.79 | CYP11B1 (0.66) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL16012920 | 0.79 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL14778695 | 0.78 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP1A2CYP17A1CYP19A1 | |
| SCHEMBL31260111 | 0.77 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP1A2 | |
| SCHEMBL14789872 | 0.77 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964628-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP11B2 OR CYP11B1) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-09-11 | — | — | EP | claimed |
| US-9458135-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | claimed |
| EP-2964628-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP1 1 B2 OR CYP1 1 B1 ) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | claimed |
| US-20160002207-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | claimed |
| WO-2014135561-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP1 1 B2 OR CYP1 1 B1 ) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | claimed |
| EP-2964628-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP11B2 OR CYP11B1) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-09-11 | — | — | EP | disclosed |
| EP-2964628-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP11B2 OR CYP11B1) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-9458135-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458135-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2964628-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP1 1 B2 OR CYP1 1 B1 ) INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002207-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002207-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014135561-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP1 1 B2 OR CYP1 1 B1 ) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135561-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES AS ALDOSTERONE SYNTHASE (CYP1 1 B2 OR CYP1 1 B1 ) INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002207-A1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | RECQL, QDPR, NDUFC2 | CYP11B1 847/4885CYP11B2 684/4885CYP1A2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.